Dossier · Defunct or wound down · 6 independent sources
Donisi Health
Last updated: Jul 31, 2026
Donisi Health, formerly associated with ContinUse Biometrics, developed Gili Pro BioSensor, a contact-free optical device and software system for spot measurement of heart rate and respiratory rate. The company achieved FDA De Novo classification for the device, but current public evidence points to an inactive or wound-down operating position rather than a clearly active growth-stage startup.
Company Overview
Donisi Health was an Israeli medical-device company founded in 2015 and publicly associated with the earlier ContinUse Biometrics name. Its core product, the Gili Pro BioSensor, used an optical module to capture motion-vibration signals from an illuminated surface and infer physiological information without electrodes, patches, or a wearable. The FDA De Novo decision for DEN200038 is specific and important: it classified a Class II hardware-and-software device for optical camera-based spot measurement of heart rate and respiratory rate, for adult patients in hospital, outpatient, medical-care, or clinical-research settings under professional supervision. That is a meaningful regulatory and engineering milestone, but it should not be expanded into a claim that every advertised cardiopulmonary parameter or home-monitoring outcome was FDA-cleared.
The technology mattered because it targeted a real source of friction in remote and repeated measurement. A seated patient could be measured without attaching sensors, which could improve setup time, comfort, adherence, and infection-control logistics in selected workflows. Company and ecosystem materials also described a broader platform involving a tabletop device, cloud services, a mobile application, and dashboards, with research and commercial messaging around chronic heart failure and pulmonary-congestion monitoring. Those broader claims are relevant product context, not proof of current deployment, reimbursement, clinical utility at scale, or a durable moat. The defensible technical questions are calibration against clinical reference devices, performance across lighting and clothing conditions, motion tolerance, demographic robustness, false-alert rates, cybersecurity, and the repeatability of the complete hardware-software workflow rather than an isolated laboratory result.
Historically, Donisi attracted substantial ecosystem attention. Public startup databases describe a 2016 seed round, a 2018 Series B associated with ContinUse Biometrics, later convertible-debt activity, strategic and venture participation, and recognition in Israeli medical-innovation competitions. Public materials also referenced patents, clinical validation work, a BIRD-supported development relationship involving Dell, and FDA progress. These signals establish that the company reached a serious development and regulatory stage; they do not establish current revenue, active customers, manufacturing scale, an operating team, or a successful transition from pilot projects to repeatable sales. Public headcount estimates are inconsistent, and the company website no longer passed a current DNS/HTTP check during this review.
Competitive pressure was structurally high. Donisi’s non-contact approach competed with conventional clinical monitors, adhesive and wearable remote-patient-monitoring devices, radar and camera-based vital-sign systems, and better-capitalized digital-health platforms that already owned provider relationships and data workflows. A successful commercialization path would have required not only measurement accuracy but also clinical workflow integration, regulatory maintenance, procurement approvals, data protection, support infrastructure, and a clear economic case for avoiding visits or readmissions. The available public record does not show enough current evidence to determine whether those hurdles were overcome.
The dual-use case is technically plausible but should remain bounded. Contact-free heart and respiratory-rate sensing could support operator or driver safety, emergency triage, austere-care monitoring, and continuity-of-operations workflows where attaching sensors is slow or impractical. However, the public sources reviewed describe healthcare and safety applications, not defense contracts, classified work, military validation, or deployment with security agencies. The strategic value is therefore historical and capability-based: Donisi is a useful Israeli example of optical biosensing moving through medical-device regulation, while its present strategic relevance and operational availability are impaired by the unresolved corporate and website status. Any renewed diligence would need to confirm legal status, asset ownership, IP control, product availability, regulatory maintenance, customer contracts, and whether a successor entity is commercializing the technology.
Dual-Use Assessment
The underlying optical physiological-sensing capability has substantive but unproven security and defense adjacency: it could reduce instrumentation burden in operator safety, emergency triage, austere care, or fleet-readiness workflows. Public evidence supports healthcare and medical-device use, not defense customers or contracts. Because the company appears to have open insolvency or liquidation-related proceedings and its current operating status is unresolved, dual-use describes the technology's applicability rather than current defense readiness.
Strategic Fit Assessment
Donisi is not an active priority signal on the current evidence. Its historical regulatory milestone, optical sensing IP, and medical-device development record are strategically relevant, but public records indicate open insolvency or liquidation-related proceedings, the official domain is not currently reachable, and current management, customers, financing, and asset ownership are not sufficiently verifiable. The record merits technology and asset-recovery diligence only if a successor, acquirer, or court-authorized disposition can be identified; it should not be treated as a live strategic-screening signal without that confirmation.
Strategic Value to U.S.-Israel Alliance
The company has historical strategic value as an Israeli deep-tech case study in contact-free optical biosensing, medical-device regulation, and the translation of physiological sensing into remote-care workflows. The technology could be relevant to resilience and human-state monitoring portfolios, but that value is contingent on recoverable IP, a functioning product, maintained regulatory rights, and a viable successor operator. Current strategic relevance is therefore a diligence lead rather than an operating capability or validated defense asset.
Key Technologies
- Optical camera-based motion-vibration sensing
- Non-contact heart-rate and respiratory-rate measurement
- Signal processing for micro-movement and physiological feature extraction
- AI-assisted cardiopulmonary trend and alert analytics
- Tabletop medical-device hardware with cloud, mobile, and dashboard workflow
- Clinical validation and Class II medical-device regulatory controls
Use Cases & Applications
- Clinician-supervised spot measurement in hospitals and outpatient settings
- Remote patient-monitoring support for chronic cardiopulmonary disease
- Hospital-at-home and post-discharge observation workflows
- Research measurement of heart and respiratory rate without attached sensors
- Emergency triage or surge-care measurement where rapid setup matters
- Driver or operator safety screening where contact-free sensing is operationally useful
- Austere-care or continuity-of-operations monitoring, subject to new validation
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Open-web verification is limited. Readers should confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 6 public references used for company identity, status, positioning, or material-claim review.
Verification note: public information is limited; this entry is retained for ecosystem-mapping purposes and should not be relied on without further confirmation.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- FDA De Novo Decision Summary DEN200038 Primary regulatory source: describes the Gili Pro BioSensor optical module, intended spot-measurement use for heart rate and respiratory rate, professional-use context, and Class II classification.
- Federal Register: Gili Pro BioSensor classification Regulatory notice identifying ContinUse Biometrics Ltd. as the De Novo requester and documenting the Class II device classification and special-controls framework.
- MobiHealthNews: Israeli startup Donisi Health lands De Novo Contemporaneous reporting on Donisi's identity, Tel Aviv base, Gili Pro product, and FDA milestone.
- Startup Nation Finder: Donisi Health historical profile Historical ecosystem profile covering the ContinUse/Donisi naming lineage, founded date, funding history, products, and historical business positioning; not evidence of current activity.
- CheckID: Donisi Health Ltd. company record Public company-record aggregation reporting open insolvency and liquidation-related proceedings and a 2024 charge update; requires confirmation against the Israeli registrar or court docket before legal conclusions.
- Donisi Health historical official domain Historically cited official web presence; the domain did not resolve in the local HTTP/DNS check performed for this update, so it is not retained as the current website field.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the Semiconductors & DeepTech Hardware sector page for market context, related subcategories, and other Israeli companies in this part of the database.